Abbott Laboratories $ABT Shares Sold by Hantz Financial Services Inc.

Hantz Financial Services Inc. decreased its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 30.1% in the third quarter, Holdings Channel reports. The institutional investor owned 122,770 shares of the healthcare product maker’s stock after selling 52,786 shares during the quarter. Hantz Financial Services Inc.’s holdings in Abbott Laboratories were worth $12,135,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in ABT. BlackRock Inc. grew its stake in shares of Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after acquiring an additional 6,769,518 shares during the last quarter. State Street Corp increased its holdings in shares of Abbott Laboratories by 1.7% during the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after acquiring an additional 1,350,766 shares in the last quarter. Bank of America Corp DE purchased a new position in shares of Abbott Laboratories in the 2nd quarter worth about $1,603,607,000. Deutsche Bank AG raised its position in shares of Abbott Laboratories by 18.6% in the 2nd quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock worth $1,515,963,000 after purchasing an additional 2,614,965 shares during the last quarter. Finally, Legal & General Group Plc bought a new position in Abbott Laboratories in the 2nd quarter worth about $1,082,524,000. 75.18% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on ABT shares. UBS Group cut their price objective on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. TD Cowen reduced their price objective on shares of Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating for the company in a research note on Thursday, October 22nd. Royal Bank Of Canada decreased their target price on shares of Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Thursday, October 22nd. Wells Fargo & Company upped their target price on shares of Abbott Laboratories from $112.00 to $119.00 and gave the stock an “overweight” rating in a research note on Thursday, October 22nd. Finally, BTIG Research dropped their target price on shares of Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating on the stock in a research note on Thursday, October 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $118.32.

Get Our Latest Research Report on ABT

Insider Activity

In other news, EVP Mary Moreland sold 3,500 shares of the firm’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $116.00, for a total transaction of $406,000.00. Following the sale, the executive vice president owned 100,791 shares of the company’s stock, valued at $11,691,756. This trade represents a 3.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Trading Up 0.1%

Shares of NYSE:ABT opened at $108.59 on Monday. The company has a market cap of $188.08 billion, a P/E ratio of 40.52, a PEG ratio of 1.90 and a beta of 0.54. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.45 and a quick ratio of 1.00. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $132.02. The stock’s fifty day moving average price is $103.93 and its 200-day moving average price is $101.74.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, meeting the consensus estimate of $1.42. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The company had revenue of $13.01 billion for the quarter, compared to analysts’ expectations of $12.99 billion. During the same period last year, the firm posted $1.30 earnings per share. Abbott Laboratories’s revenue was up 14.5% compared to the same quarter last year. Sell-side analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, October 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio is currently 94.03%.

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Read More

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.